ASCO 2010 renal intro

Article

Watch this page for ONCOLOGY’s on-site coverage of the annual meeting: Internationally regarded oncologists give exclusive interviews and expert perspective reports of the highlights of this year’s meeting. See the links below for ASCO Renal Cell Carcinoma session coverage from RCC experts Andrew J. Armstrong, MD, MSc, Duke Comprehensive Cancer Center, and Robert J. Motzer, MD, MSKK

Watch this page for ONCOLOGY’s on-site coverage of the annual meeting: Internationally regarded oncologists give exclusive interviews and expert perspective reports of the highlights of this year’s meeting. See the links below for ASCO Renal Cell Carcinoma session coverage from RCC experts Andrew J. Armstrong, MD, MSc, Duke Comprehensive Cancer Center, and Robert J. Motzer, MD, MSKK

Recent Videos
3 experts in this video
3 experts in this video
Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
3 experts in this video
3 experts in this video
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
The 2 main pafolacianine components, a folate analog and a dye, are commonly used in other medical applications.
Related Content
Cosibelimab has been approved by the FDA as a treatment for patients with cutaneous squamous cell carcinoma.

FDA Approves Cosibelimab in Cutaneous Squamous Cell Carcinoma

Tim Cortese
December 13th 2024
Article

Cosibelimab has been approved by the FDA as a treatment for patients with cutaneous squamous cell carcinoma.

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

Ensuring Holistic, Individualized Transitions of Care for Cancer Survivors

Andrew M. Evens, DO, MBA, MSc
December 9th 2024
Podcast

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

More than 80% of the SENTRY trial population had alleviation of their myelofibrosis-associated symptoms following treatment with selinexor/ruxolitinib.

Selinexor Combo Shows Activity in Myelofibrosis Spleen Responses, Symptoms

Morgan Bayer
December 13th 2024
Article

More than 80% of the SENTRY trial population had alleviation of their myelofibrosis-associated symptoms following treatment with selinexor/ruxolitinib.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

Kelley A. Rone, DNP, RN, AGNP-c
December 2nd 2024
Podcast

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Of 18 patients with BRCA-mutated ER+/HER2– breast cancer, 3 had a pathological complete response when treated with niraparib plus dostarlimab.

Niraparib/Dostarlimab Shows Promise in BRCA+ ER+/HER2– Breast Cancer

Ariana Pelosci
December 13th 2024
Article

Of 18 patients with BRCA-mutated ER+/HER2– breast cancer, 3 had a pathological complete response when treated with niraparib plus dostarlimab.

Response Rates Were Improved for Camrelizumab/Chemo vs Chemo in TNBC

Response Rates Were Improved for Camrelizumab/Chemo vs Chemo in TNBC

Kristi Rosa
December 13th 2024
Article

The phase 3 CamRelief study reported a pathologic complete response rate of 56.8% for camrelizumab plus chemo compared with 44.7% for chemo alone.